161 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
32
Ending by 2030
Jan 2027
Next term end
65
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2029 · High confidence
Also notable
Ends Jul 2029 · High confidence
Also notable
Ends Dec 2039 · High confidence
C5aR ANTAGONISTS
US 10,660,897
Cited by 18 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation
US 7,884,110
Cited by 43 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1/PD-L1 Inhibitor
US 11,304,952
Cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 25 to 27, 2026 · next Dec 25
- 4 fees due Jan 2 to 25, 2027 · next Jan 2
- 3 fees due Feb 1 to 27, 2027 · next Feb 1
- 9 fees due Mar 3 to 24, 2027 · next Mar 3
- 7 fees due Apr 3 to 27, 2027 · next Apr 3
- 5 fees due May 5 to 26, 2027 · next May 5
- 3 fees due Jun 5 to 19, 2027 · next Jun 5
- 6 fees due Jul 9 to 30, 2027 · next Jul 9
- 4 fees due Aug 6 to 25, 2027 · next Aug 6
- 2 fees due Sep 10 to 24, 2027 · next Sep 10
- 2 fees due Oct 2 to 9, 2027 · next Oct 2
- 3 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- 3 of the patents on this record were granted since Aug 16, 2026
- 5 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 65 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Inhibitors of Human Tumor-Expressed CCXCKR2 | 16 in force | to Jul 2032 |
| Method of Treating Pancreatic Cancer | 6 in force | to Jun 2037 |
| Substituted Anilines as CCR(4) Antagonists | 6 in force | to Jan 2033 |
| C5aR ANTAGONISTS | 6 in force | to Feb 2031 |
| CXCR7 Antagonists | 5 in force | to Nov 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,790,726 | Monocyclic and Bicyclic Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 7,524,845 | Azaindazole Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,637,043 | Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof In force · High confidence | In force | High confidence | |
| US 7,807,704 | Bicyclic, Nitrogen-Containing Compounds Modulating CXCR4 And/Or CCXCKR2 In force · High confidence | In force | High confidence | |
| US 7,649,011 | Inhibitors of Human Tumor-Expressed CCXCKR2 In force · High confidence | In force | High confidence | |
| US 7,777,035 | Azaindazole Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 7,572,600 | Enzymatic Activities in Chemokine-Mediated Inflammation In force · High confidence | In force | High confidence | |
| US 7,671,069 | Tricyclic, Heteroaromatic Compounds Modulating CXCR4 And/ or CXCR7 In force · High confidence | In force | High confidence | |
| US 7,683,176 | Triazolyl Pyridyl Benzenesulfonamides In force · High confidence | In force | High confidence | |
| US 7,718,683 | Triazolyl Phenyl Benzenesulfonamides In force · High confidence | In force | High confidence |
Also on record, not counted in the 161: 4 patents in force now held by others · 39 patents ended · 9 applications pending · 74 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.